Patient Characteristics
| Characteristic | All patients | Initial diagnosis | PSA persistence after surgery | PSA recurrence |
| No. of patients | 121 | 50 | 11 | 60 |
| Median age (y) | 71 (50–84) | 72 (50–84) | 67 (53–75) | 69 (50–84) |
| Gleason score (n) | ||||
| ≤6 | 6 (5.0%) | 4 (8.0%) | — | 2 (3.3%) |
| 7 | 59 (48.8%) | 18 (36.0%) | 2 (18.2%) | 39 (65.0%) |
| ≥8 | 55 (45.5%) | 28 (56.0%) | 9 (81.8%) | 18 (30.0%) |
| Unknown | 1 (0.8%) | — | — | 1 (1.7%) |
| Median iPSA (ng/mL) | 9.95 (1.40–520.00) | 11.9 (3.50–313.13) | 18.58 (5.20–87.55) | 9.14 (1.40–520.00) |
| Nadir PSA (ng/mL) | 0.09 (<0.01–9.70) | — | 1.36 (0.53–9.70) | 0.07 (<0.01–3.00) |
| PSA at PET (ng/mL) | 3.06 (0.03–41.24) | 9.76 (0.06–37.10) | 1.27 (0.03–9.70) | 1.10 (0.10–41–24) |
| Risk group according to D’Amico (n) | ||||
| Low | 3 (2.5%) | 3 (6.0%) | — | — |
| Intermediate | 12 (9.9%) | 9 (18.0%) | — | 3 (5.0%) |
| High | 106 (87.6%) | 38 (76.0%) | 11 (100.0%) | 57 (95.0%) |
| Ongoing ADT (n) | ||||
| Yes | 26 (21.5%) | 12 (24.0%) | 5 (45.5%) | 9 (15.0%) |
| No | 95 (78.5%) | 38 (76.0%) | 6 (54.5%) | 51 (85.0%) |
| Prior RP only | 34 (28.1%) | — | 11 (100.0%) | 23 (38.3%) |
| Prior RT only | 5 (4.1%) | — | — | 5 (8.3%) |
| Prior RP and RT | 32 (26.4%) | — | — | 32 (53.3%) |
| Surgery margin | ||||
| R0 | 40 (33.1%) | — | 2 (18.2%) | 38 (69.1%) |
| R1 | 24 (19.8%) | — | 9 (81.8%) | 15 (27.3%) |
| Rx | 2 (1.7%) | — | — | 2 (3.6%) |
iPSA = initial prostate-specific antigen serum level; ADT = androgen deprivation therapy; RP = radical prostatectomy; RT = radiotherapy.
Data in parentheses are ranges unless otherwise indicated.